Newly Diagnosed With Ovarian Cancer: Why Genetic Testing Is Commonly Recommended
Genetic testing is recommended for most people diagnosed with ovarian cancer — even those with no obvious family history. This page explains why and what it means for your situation.
What You Should Know Right Away
- Unlike most cancer types, ovarian cancer has a high rate of hereditary causes. Approximately 15-20% of ovarian cancers are linked to an inherited gene mutation, most commonly BRCA1 or BRCA2.
- NCCN guidelines recommend genetic counseling and testing for all patients diagnosed with ovarian, fallopian tube, or peritoneal cancer — regardless of family history.
- A positive hereditary result can affect treatment options, including eligibility for PARP inhibitors, which are targeted therapies specifically approved for BRCA-associated ovarian cancer.
- Testing also has implications for first-degree relatives who may carry the same mutation and benefit from increased screening.
What Hereditary Testing Means With an Ovarian Cancer Diagnosis
The BRCA1 and BRCA2 genes are the most common hereditary causes of ovarian cancer, but not the only ones. Lynch syndrome genes (MSH2, MLH1, MSH6, PMS2) and other mutations can also increase ovarian cancer risk. A comprehensive panel tests all clinically significant genes.
Because hereditary ovarian cancer is more common than hereditary breast cancer proportionally, genetic testing is recommended universally after diagnosis — not just for patients with family history. The absence of family history does not rule out a hereditary mutation.
What Usually Happens Next
Your oncologist may refer you for genetic counseling or may order testing directly. If testing has not yet been initiated, a genetic counselor can coordinate it and ensure the right panel is ordered.
Results typically take one to two weeks. If a mutation is found, your oncologist and genetic counselor will discuss what it means for your treatment, surveillance, and family.
Why Ovarian Cancer Often Triggers Genetic Testing Even Without Family History
Hereditary rate is higher than most cancer types
Approximately 15-20% of ovarian cancers have a hereditary cause — significantly higher than breast cancer (5-10%) or colorectal cancer (3-5%). This is why universal testing is recommended, not just testing for patients with visible family history.
PARP inhibitor eligibility
If a BRCA1 or BRCA2 mutation is identified, you may be eligible for PARP inhibitors — a class of targeted therapy specifically approved for BRCA-associated ovarian cancer. This is one of the most direct ways that genetic test results affect treatment decisions.
Germline vs somatic testing
Your oncologist may order tumor (somatic) testing separately from germline (hereditary) testing. These are not the same test. Germline testing tells you and your family about inherited risk. Both may be relevant to your treatment planning.
Lynch syndrome and ovarian cancer
Lynch syndrome, caused by mutations in mismatch repair genes, also increases ovarian cancer risk. A comprehensive hereditary panel covers Lynch syndrome genes in addition to BRCA1 and BRCA2.
What Your Diagnosis May Mean for Your Family
If a BRCA1, BRCA2, or Lynch syndrome mutation is identified, first-degree relatives have approximately a 50% chance of carrying the same mutation. Sisters are often prioritized given shared ovarian and breast cancer risk.
Daughters are particularly relevant for BRCA-associated risk — ovarian cancer surveillance and risk-reduction conversations typically begin in their 30s for carriers.
- First-degree relatives (parents, siblings, children) — 50% chance if mutation identified
- Sisters face the same elevated ovarian and breast cancer risks if mutation is shared
- Daughters can be tested as adults and plan surveillance accordingly
How LifeShield Can Help
Comprehensive hereditary panel
Covers BRCA1, BRCA2, Lynch syndrome genes, and all other clinically significant hereditary ovarian cancer genes
Genetic counseling
Pre-test and post-test sessions with a board-certified genetic counselor experienced in hereditary gynecologic cancer
Treatment coordination support
Results summary formatted to share with your oncology team, including PARP inhibitor eligibility implications
Family cascade support
Guidance for relatives who want to understand their own risk
Reviewed by LifeShield Medical Team · Last reviewed March 2026
Frequently Asked Questions
Yes. NCCN guidelines recommend genetic counseling and testing for all patients diagnosed with ovarian, fallopian tube, or peritoneal cancer, regardless of family history. The hereditary rate for ovarian cancer is high enough that universal testing is the clinical standard.
Germline testing analyzes your inherited DNA to identify hereditary mutations that may have contributed to your cancer and that your relatives may carry. Somatic testing analyzes the tumor itself for acquired mutations that may affect treatment eligibility. Both may be relevant, but they serve different purposes. LifeShield provides germline testing.
Yes. BRCA1 and BRCA2 mutations are associated with eligibility for PARP inhibitors, a class of targeted therapy approved for BRCA-associated ovarian cancer. Your oncologist will advise on whether this applies to your specific situation.
A negative family history does not rule out a hereditary mutation. Approximately 15-20% of ovarian cancers have a hereditary cause, and many people with hereditary mutations have no visible family history — because relatives who carried the mutation may not have developed cancer, or family history may not have been communicated.
Most eligible patients qualify for coverage when NCCN criteria are met. A diagnosis of ovarian, fallopian tube, or peritoneal cancer typically meets those criteria. LifeShield provides insurance support and superbill assistance for all patients.
Ready to Take the Next Step?
When you are ready, a licensed genetic counselor can help you understand your options and build a clear plan.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is based on published NCCN clinical guidelines and peer-reviewed research. Always consult a qualified healthcare provider for medical decisions. LifeShield content is reviewed by board-certified genetic counselors.